Cargando…

Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial

OBJECTIVE: To examine whether treatment with epigallocatechin gallate (EGCG) influences progression of brain atrophy, reduces clinical and further radiologic disease activity markers, and is safe in patients with progressive multiple sclerosis (PMS). METHODS: We enrolled 61 patients with primary or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rust, Rebekka, Chien, Claudia, Scheel, Michael, Brandt, Alexander U., Dörr, Jan, Wuerfel, Jens, Klumbies, Katharina, Zimmermann, Hanna, Lorenz, Mario, Wernecke, Klaus-Dieter, Bellmann-Strobl, Judith, Paul, Friedemann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954462/ https://www.ncbi.nlm.nih.gov/pubmed/33622766 http://dx.doi.org/10.1212/NXI.0000000000000964

Ejemplares similares

Retinal Thickness Analysis in Progressive Multiple Sclerosis Patients Treated With Epigallocatechin Gallate: Optical Coherence Tomography Results From the SUPREMES Study
por: Klumbies, Katharina, et al.
Publicado: (2021)

Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial
por: Bellmann-Strobl, Judith, et al.
Publicado: (2021)

Vitamin D and Disease Severity in Multiple Sclerosis—Baseline Data From the Randomized Controlled Trial (EVIDIMS)
por: Bäcker-Koduah, Priscilla, et al.
Publicado: (2020)

Tea-induced improvement of endothelial function in humans: No role for epigallocatechin gallate (EGCG)
por: Lorenz, Mario, et al.
Publicado: (2017)

Temporal visual resolution and disease severity in MS
por: Ayadi, Noah, et al.
Publicado: (2018)

Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot study
por: Wieder, Laura, et al.
Publicado: (2013)

Effect of vitamin D supplementation on N‐glycan branching and cellular immunophenotypes in MS
por: Bäcker‐Koduah, Priscilla, et al.
Publicado: (2020)

Association of Retinal and Macular Damage with Brain Atrophy in Multiple Sclerosis
por: Dörr, Jan, et al.
Publicado: (2011)

Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial
por: Dörr, Jan, et al.
Publicado: (2018)

Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1
por: Janssen, Antonia, et al.
Publicado: (2015)

Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
por: Paul, Friedemann, et al.
Publicado: (2008)

High-dose vitamin D supplementation in multiple sclerosis – results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial
por: Dörr, Jan, et al.
Publicado: (2020)

Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration
por: Brandt, Alexander U., et al.
Publicado: (2021)

Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue
por: Gaede, Gunnar, et al.
Publicado: (2017)

Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) – preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial
por: Albert, Christian, et al.
Publicado: (2020)

Skin Protective Effect of Epigallocatechin Gallate
por: Kim, Eunji, et al.
Publicado: (2018)

Role of Epigallocatechin Gallate in Glucose, Lipid, and Protein Metabolism and L-Theanine in the Metabolism-Regulatory Effects of Epigallocatechin Gallate
por: Lin, Ling, et al.
Publicado: (2021)

Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation
por: Cooper, Graham, et al.
Publicado: (2021)

Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?
por: Mähler, Anja, et al.
Publicado: (2013)

Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy
por: Granja, Andreia, et al.
Publicado: (2016)

Food-Grade Encapsulation Systems for (−)-Epigallocatechin Gallate
por: Shi, Meng, et al.
Publicado: (2018)

Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems
por: Granja, Andreia, et al.
Publicado: (2017)

Effect of Epigallocatechin Gallate on Viability of Kudoa septempunctata
por: Shin, Sang Phil, et al.
Publicado: (2020)

Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study
por: Chien, Claudia, et al.
Publicado: (2019)

Effects of epigallocatechin-3-gallate combined with ascorbic acid and glycerol on the stability and uric acid-lowering activity of epigallocatechin-3-gallate
por: Xie, Qianjin, et al.
Publicado: (2021)

Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders
por: Ayadi, Noah, et al.
Publicado: (2021)

Epigallocatechin-3-gallate and Epigallocatechin-3-O-(3-O-methyl)-gallate Enhance the Bonding Stability of an Etch-and-Rinse Adhesive to Dentin
por: Yu, Hao-Han, et al.
Publicado: (2017)

Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2018)

Effects of (-)-epigallocatechin gallate on RPE cell migration and adhesion
por: Chan, Chi-Ming, et al.
Publicado: (2010)

Broad inhibition of plasmodium falciparum cytoadherence by (+)-epigallocatechin gallate
por: Patil, Pradeep R, et al.
Publicado: (2011)

Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
por: Singh, Neha Atulkumar, et al.
Publicado: (2016)

Inhibitory Effects of (−)-Epigallocatechin-3-gallate on Esophageal Cancer
por: Wang, Liu-Xiang, et al.
Publicado: (2019)

The Effect of Ultrasound, Oxygen and Sunlight on the Stability of (−)-Epigallocatechin Gallate
por: Zeng, Jiajun, et al.
Publicado: (2018)

Melatonin and (−)-Epigallocatechin-3-Gallate: Partners in Fighting Cancer
por: Zhang, Lingyun, et al.
Publicado: (2019)

Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate
por: Min, Kyoung-jin, et al.
Publicado: (2014)

Effects of Epigallocatechin-3-Gallate on Autophagic Lipolysis in Adipocytes
por: Kim, Sang-Nam, et al.
Publicado: (2017)

Preclinical Activities of Epigallocatechin Gallate in Signaling Pathways in Cancer
por: Sharifi-Rad, Mehdi, et al.
Publicado: (2020)

Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
por: Cheong, Yucheol, et al.
Publicado: (2021)

The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma
por: Li, Dongming, et al.
Publicado: (2023)

Zeolites with Divalent Ions as Carriers in the Delivery of Epigallocatechin Gallate
por: Sandomierski, Mariusz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5topr553dv9dei5cmk4qlkpld6